Retrospective observational study to evaluate the effectiveness, safety and tolerability in real life in Spain of encorafenib plus cetuximab (CE) in the second-line treatment of metastatic colorectal cancer with BRAFV600E mutation. CONFIDENCE
INDEPENDENT POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: DIGESTIVE TUMORS TREATMENT GROUP
- Execution start: 30/11/2021
- End of execution: 30/04/2022
- IP: ENCARNA GONZALEZ FLORES